BRPI0616604A2 - mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica - Google Patents

mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica Download PDF

Info

Publication number
BRPI0616604A2
BRPI0616604A2 BRPI0616604-0A BRPI0616604A BRPI0616604A2 BR PI0616604 A2 BRPI0616604 A2 BR PI0616604A2 BR PI0616604 A BRPI0616604 A BR PI0616604A BR PI0616604 A2 BRPI0616604 A2 BR PI0616604A2
Authority
BR
Brazil
Prior art keywords
core
wrap
polymer
hours
particle
Prior art date
Application number
BRPI0616604-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael J Cope
Paul Mansky
Futian Liu
Han-Ting Chang
Dominique Charmot
Eric Connor
Kalpesh Biyani
Mingjun Liu
Yan Chen
Tony Kwok-Kong Mong
Original Assignee
Ilypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilypsa Inc filed Critical Ilypsa Inc
Publication of BRPI0616604A2 publication Critical patent/BRPI0616604A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0616604-0A 2005-09-30 2006-10-02 mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica BRPI0616604A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72307305P 2005-09-30 2005-09-30
US60/723073 2005-09-30
PCT/US2006/038602 WO2007041569A1 (en) 2005-09-30 2006-10-02 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal

Publications (1)

Publication Number Publication Date
BRPI0616604A2 true BRPI0616604A2 (pt) 2012-12-25

Family

ID=37607162

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616604-0A BRPI0616604A2 (pt) 2005-09-30 2006-10-02 mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica

Country Status (11)

Country Link
US (5) US8617609B2 (cg-RX-API-DMAC10.html)
EP (1) EP1928476A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009510126A (cg-RX-API-DMAC10.html)
KR (1) KR20080059265A (cg-RX-API-DMAC10.html)
CN (1) CN101316601A (cg-RX-API-DMAC10.html)
AU (1) AU2006299449B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0616604A2 (cg-RX-API-DMAC10.html)
CA (1) CA2624170C (cg-RX-API-DMAC10.html)
DE (1) DE112006002618T5 (cg-RX-API-DMAC10.html)
GB (1) GB2446077B (cg-RX-API-DMAC10.html)
WO (1) WO2007041569A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101153035B1 (ko) * 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
JP2009510126A (ja) 2005-09-30 2009-03-12 レリプサ, インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
EP4201408B1 (en) * 2008-08-22 2025-06-25 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
AU2013204879B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
EP3572143B1 (en) 2009-08-26 2021-06-02 Evoqua Water Technologies Pte. Ltd. Ion exchange membranes
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
CN103237591B (zh) 2010-10-15 2016-04-13 伊沃夸水处理技术有限责任公司 制备用于制造阳离子交换膜的单体溶液的方法
EP2627447B1 (en) * 2010-10-15 2019-12-11 Evoqua Water Technologies LLC Anion exchange membranes and process for making
CA2827056C (en) 2011-02-11 2020-07-14 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN110028603A (zh) 2011-06-27 2019-07-19 瑞立普萨公司 用于将聚合酯转化为聚合酸的方法
EP2570183A1 (en) * 2011-09-15 2013-03-20 InstrAction GmbH Sorbent comprising on its surface an aliphatic unit for the purification of organic molecules
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
MX2015000381A (es) 2012-07-11 2015-11-23 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
CN104703697B (zh) 2012-10-04 2018-11-23 懿华水处理技术有限责任公司 高性能的阴离子交换膜及其制造方法
ES3059226T3 (en) * 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia
EP2906330B1 (en) 2012-10-11 2020-06-17 Evoqua Water Technologies LLC Coated ion exchange membranes
HRP20251373T1 (hr) 2012-10-22 2025-12-19 Zs Pharma, Inc Mikroporozni cirkonijev silikat za liječenje hiperkalijemije
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
CN105597699B (zh) * 2016-01-29 2018-07-13 四川农业大学 一种高效吸附Cu2+的改性蚯蚓粪微球、制备方法及应用
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
AU2019346563B2 (en) 2018-09-25 2025-07-17 Evoqua Water Technologies Llc Monovalent selective cation exchange membrane

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3416884A (en) * 1966-11-04 1968-12-17 Nat Lead Co Crystalline zirconium phosphates
FR2171934B1 (cg-RX-API-DMAC10.html) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3031737A1 (de) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse
DE3149136A1 (de) * 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
KR920006865B1 (ko) 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
DK0656029T3 (da) * 1992-08-20 1999-02-15 Du Pont Tværbundne polymere ammoniumsalte
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
WO1994027619A1 (en) * 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
EP0654461B1 (de) 1993-11-22 1997-12-03 Bayer Ag Verfahren zur Herstellung von Diarylcarbonaten
WO1995014531A1 (en) 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
JPH09208477A (ja) * 1996-01-30 1997-08-12 Mitsubishi Chem Corp イオン交換樹脂から成る経口医薬品
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
AU3649697A (en) 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
JP2001526212A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
JP3596742B2 (ja) * 1998-07-31 2004-12-02 日研化学株式会社 陽イオン交換樹脂製剤
KR100440544B1 (ko) * 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
CA2355829A1 (en) 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
DE60027309T2 (de) 1999-07-02 2006-08-31 Symyx Technologies, Inc., Santa Clara Polymerverzweigungen zur immobilisierung von molekülen auf oberflächen oder substraten, wobei die polymere wasserlösliche oder wasserdispergierbare segmente und sonden aufweisen
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20030027789A1 (en) * 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
US6908609B2 (en) * 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
AU2002242103A1 (en) * 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
WO2003062372A2 (en) * 2001-10-02 2003-07-31 The Regents Of The University Of California Nanoparticle assembled hollow spheres
US20040010589A1 (en) 2002-07-11 2004-01-15 Keenan Donald M. Method to generate and manipulate visitor traffic to on-line and off-line business sites
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
CA2516457C (en) * 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
NL1026650C1 (nl) 2003-09-03 2005-03-07 Wolf Ciecierski Standaard, in het bijzonder voor het rechtop houden van een document en/of laptop.
JP2005112838A (ja) * 2003-10-10 2005-04-28 Takuya Kitami キチンキトサンカルシウムによる高カリウム血症改善剤
AU2004285450B2 (en) * 2003-10-20 2010-01-14 Gregory K. Frykman Zeolite molecular sieves for the removal of toxins
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
KR101153035B1 (ko) * 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7182798B2 (en) * 2004-07-29 2007-02-27 Rohm And Haas Electronic Materials Cmp Holdings, Inc. Polymer-coated particles for chemical mechanical polishing
AU2005322322B2 (en) * 2004-12-28 2010-04-01 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
JP2009510126A (ja) 2005-09-30 2009-03-12 レリプサ, インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
KR101367279B1 (ko) 2007-07-11 2014-02-28 삼성전자주식회사 클록을 내장한 데이터 신호를 전송하는 디스플레이 장치
NL2009207C2 (nl) 2012-07-19 2013-05-01 Driessen Blueberries B V Inrichting geschikt voor het oogsten van aan een plant hangend fruit alsmede een werkwijze voor het oogsten van het oogsten van aan een plant hangend fruit.

Also Published As

Publication number Publication date
WO2007041569A1 (en) 2007-04-12
US10058567B2 (en) 2018-08-28
AU2006299449A1 (en) 2007-04-12
US20140044804A1 (en) 2014-02-13
CN101316601A (zh) 2008-12-03
KR20080059265A (ko) 2008-06-26
CA2624170C (en) 2014-02-25
US20160193247A1 (en) 2016-07-07
GB2446077B (en) 2010-10-13
US8617609B2 (en) 2013-12-31
US9301974B2 (en) 2016-04-05
US20090155370A1 (en) 2009-06-18
JP2009510126A (ja) 2009-03-12
CA2624170A1 (en) 2007-04-12
EP1928476A1 (en) 2008-06-11
GB0806896D0 (en) 2008-05-21
US10905711B2 (en) 2021-02-02
US20130259949A1 (en) 2013-10-03
US20180133244A1 (en) 2018-05-17
GB2446077A (en) 2008-07-30
DE112006002618T5 (de) 2008-08-28
AU2006299449B2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
US10905711B2 (en) Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
BRPI0616603A2 (pt) mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
US7556799B2 (en) Ion binding polymers and uses thereof
EP1732523B9 (en) Potassium binding polymers and uses thereof
AU2018206706A1 (en) Ion binding polymers and uses thereof
WO2007038801A2 (en) Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
HK1185003B (en) Ion binding polymers and uses thereof

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B25G Requested change of headquarter approved

Owner name: ILYPSA, INC. (US)

B25A Requested transfer of rights approved

Owner name: RELYPSA, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2274 DE 05/08/2014.